Pfizer Touts Relpax Efficacy Versus Excedrin Migraine In Study
This article was originally published in The Tan Sheet
Executive Summary
Pfizer is targeting the competition from OTC analgesics in a recently published study on the superior efficacy of its Relpax (eletriptan) versus Bristol-Myers Squibb's Excedrin Migraine
You may also be interested in...
GSK’s Imigran Recovery Is First Triptan Approved For Nonprescription UK Sale
GlaxoSmithKline expects to make nonprescription Imigran Recovery (sumatriptan 50 mg) available in the UK in mid-June following approval for pharmacy sale by the Medicines & Healthcare products Regulatory Agency
GSK’s Imigran Recovery Is First Triptan Approved For Nonprescription UK Sale
GlaxoSmithKline expects to make nonprescription Imigran Recovery (sumatriptan 50 mg) available in the UK in mid-June following approval for pharmacy sale by the Medicines & Healthcare products Regulatory Agency
GSK’s Imigran Recovery Is First Triptan Approved For Nonprescription UK Sale
GlaxoSmithKline expects to make nonprescription Imigran Recovery (sumatriptan 50 mg) available in the UK in mid-June following approval for pharmacy sale by the Medicines & Healthcare products Regulatory Agency